<DOC>
	<DOCNO>NCT02556424</DOCNO>
	<brief_summary>Corticosteroids , whether inject peri- intra-ocularly , remain indispensable tool therapeutic arsenal treat inflammatory macular edema . However , year ago , triamcinolone acetonide available ophthalmologist . This molecule , develop initially rheumatological dermatological use , increasingly deploy ophthalmology , still off-label . In 2011 , delivery system dexamethasone biodegradable injectable implant vitreous cavity obtain label inflammatory macular edema . This protocol therefore design compare efficacy safety peri- intra-ocular injection corticosteroid treatment inflammatory macular edema .</brief_summary>
	<brief_title>Efficacy Tolerance Comparison Between Subconjunctival Injection Triamcinolone Intravitreal Implant Dexamethasone Treatment Inflammatory Macular Edema</brief_title>
	<detailed_description>This research compare implantation technique corticosteroid eye , two group equal size follow . This multi-center , control study , reference drug intravitreal implant 700μg dexamethasone ( Ozurdex® ) compare subconjunctival injection triamcinolone ( Kénacort retard® ) . This open , prospective , randomize study . It possible , technical reason , inject blind two product different injection route visible investigator control examination ( sub-conjunctival crystal intravitreal implant ) . However , assessment visual acuity central macular thickness perform uninformed ophthalmologist .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Patient , male female ( effective contraception premenopausal ) 18 year old Patient affiliate social security plan Patient able understand follow instruction study Patient sign informed consent Patient central macular thickness great 320μm ( Spectral Domain , 270µm Time Domain ) Patient inflammatory macular edema , unilateral bilateral ( case bilateral inflammatory macular edema , eye affect treat ) Patient infectious uveitis Patient uncontrolled active infection Patient receiving unbalanced general antiinflammatory and/or immunosuppressive and/or immunomodulatory therapy ( recent modification &lt; 1 month ) Patient history glaucoma and/or ocular hypertension eye study ( intraocular pressure ( IOP ) &gt; 25 mmHg without antiglaucoma medication &gt; 21 mmHg antiglaucoma combination therapy ) and/or cortisonecausinghypertension control antiglaucoma dual therapy Patient uncontrolled diabetes ( HbA1c &gt; 8 % ) unbalanced hypertension ( Systolic Blood Pressure &gt; 160 mmHg and/or Diastolic Blood Pressure &gt; 100mmHg ) Edematous diabetic maculopathy Patient receive triamcinolone ( subconjunctivally subtenon ) 3 month randomization , 700μg dexamethasone intravitreally 6 month randomization Suspected active ocular periocular infection , include viral disease cornea conjunctiva , active epithelial keratitis herpes simplex ( dendritic keratitis ) , vaccinia , varicella , mycobacterial infection mycoses History ocular herpes infection central serous chorioretinopathy Aphakic eye rupture posterior lens capsule Eye implant anterior chamber , iris transscleralfixated intraocular implant rupture posterior lens capsule Uncontrolled systemic inflammatory disease . Known hypersensitivity active substance one excipients Ozurdex® , Kenacort® injectable fluorescein Pregnant woman likely become pregnant nursing Patient participate another clinical trial Adult legal protection regime ( guardianship , trusteeship , `` sauvegarde de justice '' )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Ophthalmology</keyword>
	<keyword>Uveitic macular edema</keyword>
	<keyword>Triamcinolone subconjunctival injection</keyword>
	<keyword>Dexamethasone intraocular implant</keyword>
</DOC>